Prospective Study to Determine the Effect of Subconjunctival Bevacizumab (AVASTIN) in Corneal Neovascularization
Corneal Neovascularization
About this trial
This is an interventional treatment trial for Corneal Neovascularization focused on measuring corneal neovascularization, Bevacizumab (Avastin), Immunologic rejection, vascular endothelial growth factor
Eligibility Criteria
Inclusion Criteria:
- Presence of vessels in minimum one quadrant
- vessels that penetrate more than 0.5 mm of the limb, in any depth
- who had signed the informed consent
- those that could attend to frequent ophthalmologic revisions after treatment and could wait for 6 months before the surgical procedure.
Exclusion Criteria:
- Patients with urgent need of a penetrating keratoplasty, pregnancy or lactancy
- Patient that may need an additional procedure to penetrating keratoplasty.
Sites / Locations
- Asociación Para Evitar la Ceguera en México, IAP, Hospital "Dr. Luis Sánchez Bulnes"
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
A
B
Patients with corneal neovascularization of infectious etiology, steroid reactors, and know glaucoma or glaucoma suspects. They received one dose of 0.1cc of subconjunctival Bevacizumab (Avastin™ Genentech, Inc, USA) in bulbar conjunctiva, 2 mm from the limbus, according to the location of the vessels.
Patients with corneal neovascularization of any cause except for infectious disease. Patients of this group received one application of 0.1cc of subconjunctival Bevacizumab™ + 0.1cc of triamcinolone acetonide (ATLC; Grin laboratories, México city) in bulbar conjunctiva, 2 mm from de limbus, according to the location of the vessels.